Metoperan Drug Interactions

Contraindicated combination: Levodopa or dopaminergic agonists and metoclopramide have a mutual antagonism.
Combination to be avoided: Alcohol potentiates the sedative effect of metoclopramide.
Combination to be taken into account: Due to the effect of metoclopramide, the absorption of certain drugs may be modified.
Anticholinergics and morphine derivatives: Anticholinergics and morphine derivatives may both have a mutual antagonism with metoclopramide on the digestive tract motility.
Central nervous system depressants (morphine derivatives, anxiolytics, sedative H1 antihistamines, sedative antidepressants, barbiturates, clonidine and related): Sedative effects of central nervous system depressants and metoclopramide are potentiated.
Neuroleptics: Metoclopramide may have an additive effect with other neuroleptics on the occurrence of extrapyramidal disorders.
Serotonergic drugs: The use of metoclopramide with serotonergic drugs such as SSRIs may increase the risk of serotonin syndrome.
Digoxin: Metoclopramide may decrease digoxin bioavailability. Careful monitoring of digoxin plasma concentration is required.
Cyclosporine: Metoclopramide increases cyclosporine bioavailability (Cmax by 46% and exposure by 22%). Careful monitoring of cyclosporine plasma concentration is required. The clinical consequence is uncertain.
Mivacurium and suxamethonium: Metoclopramide injection may prolong the duration of neuromuscular block (through inhibition of plasma cholinesterase).
Strong CYP2D6 inhibitors: Metoclopramide exposure levels are increased when co-administered with strong CYP2D6 inhibitors such as fluoxetine and paroxetine. Although the clinical significance is uncertain, patients should be monitored for adverse reactions.
The effects of certain other drugs with potential central stimulant effects, e.g. monoamine oxidase inhibitors and sympathomimetics, may be modified when prescribed with metoclopramide and their dosage may need to be adjusted accordingly.
Aspirin, paracetamol: The effect of metoclopramide on gastric motility may modify the absorption of other concurrently administered oral drugs from the gastrointestinal tract either by diminishing absorption from the stomach or by enhancing the absorption from the small intestine (e.g. the effects of paracetamol and aspirin are enhanced).
Atovaquone: Metoclopramide injection may reduce plasma concentrations of atovaquone.